BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 737K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

9 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.EBI
Icagen
Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.EBI
Icagen
Design, syntheses, and SAR of 2,8-diazaspiro[4.5]decanones as T-type calcium channel antagonists.EBI
Icagen
Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.EBI
Icagen
Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel.EBI
Icagen
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaEBI
Icagen
AZETIDINYL PYRIMIDINES AND USES THEREOFBDB
Aerie Pharmaceuticals
TRIAZINE DERIVATIVES FOR THE TREATMENT OF TUMOURS AND NEURODEGENERATIVE DISORDERSBDB
UNIVERSITA'' DEGLI STUDI DI MILANO
COMPOUNDS AND THE USES AND PHARMACEUTICAL COMPOSITIONS THEREOFBDB
Beijing Youzhuju Network Technology Co.